Answers are grounded in this paper and cite their sources.
Measures diagnostic capacity for mpox clade Ib in Spanish labs, suggesting areas for improvement.
To assess the preparedness and diagnostic capacity of Spanish clinical microbiology laboratories to detect the emerging monkeypox virus (MPXV) Clade Ib through a nationwide external quality assessment. A blinded 16-sample panel (serum and DNA eluates) containing MPXV Clade Ib, Clade II, vaccinia, and negatives was distributed. Of 36 laboratories submitting results, 25 with clade-level capability were included. Performance versus reference was adjudicated as full, partial, or discordant concordance; species-level and clade-specific metrics were estimated, and inter-laboratory agreement summarized with simple and weighted kappa (Wilson 95% CIs; bootstrap for kappa CIs). Species-level MPXV detection was consistently strong (mean sensitivity 85%, specificity 95%). Agreement was substantial (simple kappa 0.70; weighted 0.81). For Clade Ib, mean sensitivity was 50% (range: 0%-100%) with high but variable specificity (100%). For clade II, mean sensitivity averaged 70% (25%-100%) and specificity 98% (66.7%-100%). Methodologies varied across centers: 68% used independent extraction plus commercial PCR, 20% mixed commercial extraction with in-house PCR, and 12% integrated extraction-PCR platforms. In conclusion, Spanish laboratories maintain good capacity for MPXV species-level detection, but clade discrimination-particularly for emerging Clade Ib-remains heterogeneous and suboptimal across participating centers. Expanding QC panels to include new clades and updating/validating assays should enhance national readiness for future transmission events.
No takes yet. Share an insight, caveat, or question.
Salazar et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: